Evidence map›Paper›PMID 19826251›Full record

ArticleApplied immunohistochemistry & molecular morphology : AIMM2010

BCL6, MUM1, and CD10 expression in mantle cell lymphoma.

Gabriela Gualco, Lawrence M Weiss, William J Harrington, Carlos E Bacchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied immunohistochemistry & molecular morphology : AIMM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Pleomorphic Mantle Cell Lymphoma of the Tongue Base Presenting With Dysphagia.Clinical medicine insights. Ear, nose and throat · 2019
    Article
  13. Article
  14. Article
  15. Review
  16. Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015
    Article
  17. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas.Virchows Archiv : an international journal of pathology · 2015
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Gabriela GualcoConsultoria em Patologia, Botucatu, SP, Brazil.
Lawrence M Weiss
William J Harrington
Carlos E Bacchi
Laboratório Bacchi · BRCity Of Hope National Medical Center · USUniversity of Miami · US

Funding

Targeting of EBV Latency in Burkitt's LymphomaR01CA112217 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RAMOS, JUAN CARLOS · 2006 to 2010
$1.2M
NCI NIH HHS R01 CA112217NCI NIH HHS R01CA1219-09
6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) characteristically express CD20, CD5, and cyclin-D1, carries the translocation t(11;14) (q13;q32) and typically has no expression of germinal center cell markers. So-called aberrant phenotypes such as CD5 negative and cyclin-D1-negative MCL have been described. Also few cases with CD10 and/or BCL-6 protein expression have been reported. We analyzed 127 MCL looking for the frequency of aberrant immunophenotype, CD10, BCL-6, and MUM1 expression. All cases were CD20 and cyclin-D1 positive, 96% expressed CD5, and 98% showed the t(11;14). BCL-6 expression was observed in 12% of the cases and MUM1 in 35%. No one case showed CD10 positivity in 30% or more neoplastic cells. Only 3 cases showed 10% to 20% of tumoral cells positive for CD10. MUM1 expression was observed in 67% of the BCL-6 positive cases. Thirty-two percent of the cases showed a MUM1+/BCL-6-/CD10- phenotype and 56% had a triple-negative-pattern. Aberrant phenotype is infrequent but not rare, and does not rule out a diagnosis of MCL in an otherwise typical case.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCD5 AntigensCyclin DDNA-Binding ProteinsFemaleGene Expression Regulation, LeukemicGerminal CenterHumansIn Situ Hybridization, FluorescenceLymphoma, Mantle-CellMaleMiddle AgedNeprilysinBCL6 protein, humanBiomarkers, TumorCD5 AntigensCyclin DDNA-Binding ProteinsIGH-CCND1 fusion protein, humanNeprilysinOncogene Proteins, FusionProto-Oncogene Proteins c-bcl-6

Identifiers

PMID19826251
PMCPMC2828511
OpenAlexW2058421453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.